Clinical trials: Metabolic Side Effects of Drugs
Cytochrome P450 2D6 Ultra-rapid Metabolism
CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk
The purpose of this study is to determine if non-invasive salivary genetic screening of breastfeeding mothers taking codeine will allow for the successful identification of mother-infant pairs susceptible to adverse events and to…
- Trial name
- NCT01050400
- Testing
- Cytochrome P450 2D6 (CYP2D6) genetic screening.
- Where
- Canada
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Diabetes Mellitus, Type 2, Education
Impact of Pharmacotherapeutic Education on Medication Adherence and Adverse Outcomes in Type 2 Diabetes
Type 2 diabetes mellitus (T2DM) is a chronic progressive disease that affects more than 400 million people worldwide. There are a few studies evaluating ADRs in diabetics.
- Conditions
- Diabetes Mellitus, Type 2, Education, Drug-Related Side Effects and Adverse Reactions
- Trial name
- NCT03438162
- Testing
- Education
- Where
- Croatia
- Volunteers
- 130 people
- Sponsor
- University Hospital Dubrava
Glucosephosphate Dehydrogenase Deficiency, Favism
A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency
This study will evaluate a new and safe testing method for identifying medicines that can cause problems in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals.
- Trial name
- NCT00076323
- Testing
- Primaquine
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Walter Reed Army Institute of Research (WRAIR)
Adverse Drug Reaction, Therapy Failure
Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions or Therapy Failure
Genetic makeup of a patient influences the efficacy and safety profile of a drug. This study is to summarize individual cases, where Pharmacogenetics (PGx) has been applied during pharmaceutical care.
- Trial name
- NCT04154553
- Testing
- Buccal swab, EDTA Blood sample (4.9mL), Serum sample (7.5mL)
- Where
- Switzerland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Heart Failure, Coronary Artery Disease
PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study
This is a single-center, double-arm, open-label, randomized feasibility study that will determine whether a novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and…
- Conditions
- Heart Failure, Coronary Artery Disease, Peripheral Artery Disease, Ischemia
- Trial name
- NCT05377320
- Testing
- Clinical Decision Aid, Standard Care
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Medical College of Wisconsin
Genetics of Drug Metabolism
Utility of PharmacoGenomics for Reducing Adverse Drug Effects
UPGRADE aims to see whether data from Pharmacogenomic Testing (PGx) can help physicians manage patient medication regimens and assess if the testing has an effect on reducing adverse drug reactions, hospitalizations and emergency…
- Trial name
- UPGRADE (NCT02081872)
- Where
- 41 sites in United States
- Volunteers
- 279,000 people
- Sponsor
- Companion Dx Reference Lab, LLC
Type 2 Diabetes Mellitus
Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715
10 healthy volunteers will be enrolled to each receive two subcutaneous injections of ISIS 113715 in the abdomen on Study Day 1. Each subject will receive their two injections within a 5-minute period.
- Trial name
- NCT00365781
- Testing
- ISIS 113715
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Iron-deficiency, Iron Toxicity
A Double Blind Randomised Placebo-controlled Trial to Assess the Role of Iron Repletion in Glucose Homeostasis.
In this study the investigators aim at addressing potential relationships between iron stores and glucose homeostasis. Iron (i.e.
- Conditions
- Iron-deficiency, Iron Toxicity, Glucose Metabolism Disorders (Including Diabetes Mellitus), Metabolic Side Effects of Drugs
- Trial name
- DIAFER (NCT03191201)
- Testing
- Ferric Carboxymaltose, 0.9% sodium chloride solution
- Where
- Switzerland
- Volunteers
- 32 people
- Sponsor
- Prof Gérard WAEBER
Psychotic Disorders, Schizophrenia
Antipsychotics and Risk of Hyperglycemic Emergencies
The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency.
- Conditions
- Psychotic Disorders, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT02582736
- Testing
- Olanzapine, Risperidone, atypical antipsychotics (other)
- Where
- Canada
- Volunteers
- 725,489 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Cardiac Failure, Coronary Artery Disease
Evaluation of MyoStrain™ in Clinical Practice
Evaluate MyoStrain cardiac MRI pulse sequence in Clinical practice
- Conditions
- Cardiac Failure, Coronary Artery Disease, Sarcoidosis, Amyloidosis
- Trial name
- NCT03825224
- Testing
- Diagnostic Test: Myostrain
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Kansas Medical Center
Malnutrition, Polypharmacy
Malnutrition in Older Adults: An Intervention Based on Medication Review and Individual Nutritional Plan
The project "Nutrition and Medication management in home-dwelling older adults" consist of two separate studies witch are described in the same study protocol. This is the second study in this Project.
- Conditions
- Malnutrition, Polypharmacy, Aged
- Trial name
- NCT04228900
- Testing
- Individualized plan for improvement of nutrition, Systematic drug review
- Where
- Norway
- Volunteers
- 50 people
- Sponsor
- University of Oslo
Adverse Drug Event
Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population
Introduction: Second Generation Antipsychotics (SGAs) are widely used in the pediatric population. It is currently established that SGAs may induce undesirable metabolic adverse events (AEs) such as weight gain, metabolic changes…
- Trial name
- MEMAS (NCT04395326)
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- St. Justine's Hospital
Psychotic Disorders
Side Effects of Psychiatric Medications - a Nested Case Control Cohort Historical Prospective Study
The study is designed to fill in the gaps in current knowledge by providing a more inclusive and comprehensive understanding of the potential associations between different psychiatric medications, including antipsychotics (APs)…
- Trial name
- NCT05872555
- Testing
- Psychiatric Drugs
- Where
- Israel
- Volunteers
- 22,777 people, healthy volunteers welcome
- Sponsor
- Mark Weiser, MD, Principal Investigator
Adverse Drug Events, Adverse Drug Reactions
Pharmacogenetic Testing Among Home Health Patients
Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing.
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- NCT02378220
- Testing
- Pharmacogenetic testing
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Genelex Corporation
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumors from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Conditions
- Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma
- Trial name
- NCT00004036
- Testing
- sargramostim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Psychotic Disorders, Bipolar Disorder
Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI
The purpose of this study is to compare abdominal weight gain and fat distribution in people taking aripiprazole versus risperidone or quetiapine, to people not taking any of these antipsychotic medications.
- Conditions
- Psychotic Disorders, Bipolar Disorder, Metabolic Syndrome X
- Trial name
- CALM (NCT01739127)
- Testing
- Aripiprazole, Risperidone/Quetiapine
- Where
- Canada
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Schizophrenia
Novel Candidate Genes for Treatment Response to Antipsychotics in Schizophrenia
Schizophrenia is a severe and chronic mental disorder. The lifetime risk of schizophrenia is around 1%. Its course is chronic and frequently disabling. The keystone of schizophrenia treatment is antipsychotic medications.
- Trial name
- GEXANT (NCT02205437)
- Where
- Spain
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Pharmacogenomic Drug Interaction, Side Effect of Drug
Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:
The purpose of this study is to determine whether the implementation of pre-emptive pharmacogenomic (PGx) testing of a panel of clinically relevant PGx markers, to guide the dose and drug selection for 39 commonly prescribed…
- Conditions
- Pharmacogenomic Drug Interaction, Side Effect of Drug, Ineffective Drug Action, Drug Metabolism, Poor, CYP2D6-Related
- Trial name
- PREPARE-Mayo (NCT06322238)
- Testing
- PGx panel test
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Adverse Drug Event, Effect of Drug
Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus
Objective: To evaluate the safety and efficacy of Human Insulin rDNA (Insuget) in patients with Type II Diabetes Mellitus. Study Design: Open-label, prospective, observational, single arm, multi-center, post-marketing…
- Conditions
- Adverse Drug Event, Effect of Drug, Type 2 Diabetes Treated With Insulin
- Trial name
- RISE (NCT05161741)
- Testing
- Insulin
- Where
- Pakistan
- Volunteers
- 238 people
- Sponsor
- Getz Pharma
Bipolar Disorder
Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder
The purpose of this study is to learn more about weight gain and related side effects when children are treated with antipsychotic medicine for mood disorders.
- Trial name
- PAMS (NCT00746252)
- Testing
- risperidone, aripiprazole
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Maryland, Baltimore